Results 31 to 40 of about 4,266 (228)

The potential effect of romosozumab on perioperative management for instrumentation surgery

JOR Spine
Background Age‐related changes in bone health increase the risk for complications in elderly patients undergoing orthopedic surgery. Osteoporosis is a key therapeutic target that needs to be addressed to ensure successful instrumentation surgery.
Koji Ishikawa, Soji Tani, Tomoaki Toyone, Koki Tsuchiya, Tomoko Towatari, Yusuke Oshita, Ryo Yamamura, Kazuki Wada, Takashi Nagai, Toshiyuki Shirahata, Katsunori Inagaki, Kudo Yoshifumi   +11 more
doaj   +2 more sources

Cost-effectiveness analysis of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico.

PLoS ONE
IntroductionThis study aims to assess the cost effectiveness of romosozumab versus teriparatide, both sequenced to denosumab, for the treatment of severe postmenopausal osteoporosis at very high risk of fractures in Mexican women.MethodsA Markov model ...
Juan Pablo Diaz Martinez, Therese Aubry de Maraumont, Elly Natty Sánchez, Luis Miguel Camacho Cordero, Eric Yeh   +4 more
doaj   +2 more sources

Early transition from short-term romosozumab to antiresorptive therapies: analysis of 26 cases.

Archives of Osteoporosis
This multicentre, retrospective case series analysed bone mineral density (BMD) changes in 26 patients who switched early from romosozumab (3-10 months) to antiresorptives.
Ziswiler, Hans-Rudolf, Rodriguez, Elena Gonzalez, Schmid, Gernot, Wenger, Mathias, Steiner, Christian, Popp, Albrecht, Ferrari, Serge, Oser, Sven, Reichenbach, Stephan, Lehmann, Thomas, Lamy, Olivier, Studer, Ueli, Everts-Graber, Judith, Hars, Magaly   +13 more
core   +2 more sources

High-dose romosozumab promoted bone regeneration of critical-size ulnar defect filled with demineralized bone matrix in nonhuman primates

Journal of Orthopaedic Translation
Background: Large bone defects are challenging to manage clinically and usually require treatment with bone graft or bone graft substitute. This study evaluated the effect of romosozumab, a sclerostin antibody, in combination with demineralized bone ...
Xiaodong Li, Frank Asuncion, Michael Ominsky, Qing-Tian Niu, Kristina E. Akesson, Jeffrey Wang, Jay Lieberman, Hua Zhu Ke   +7 more
doaj   +2 more sources

Risk factors and reasons for romosozumab nonadherence in a case-control study

Scientific Reports
Risk factors and reasons for romosozumab nonadherence remain unclear. This study compared patients who adhered to romosozumab therapy with those who did not to identify possible risk factors and reasons for treatment nonadherence. This case-control study
Ting-Chien Tsai, Yun-Shan Yen, Chang-Hao Lin, Ya-Chi Cheng, Yu-Sian Ding, Chen-Hao Chiang, Cheng-Yi Wu   +6 more
doaj   +2 more sources

Comparison of the Efficacy of Romosozumab and Teriparatide for the Management of Osteoporotic Vertebral Compression Fractures [PDF]

Neurospine, 2023
Objective Romosozumab is increasingly employed to manage osteoporosis. However, no studies have analyzed its effects on recent osteoporotic vertebral compression fractures (OVCFs).
Danbi Park, Seo Eun Kim, Hong Kyung Shin, Junghan Seo, Jeong Kyun Joo, Chongman Kim, Sang Hyub Lee, Jin Hoon Park   +7 more
doaj   +1 more source

Bone mineral density response to romosozumab in post-menopausal women: A prospective observational real-world study [PDF]

Bone
Background: Romosozumab is approved in Europe for severe osteoporosis in postmenopausal women at high risk of fracture including older women, but whether bone mineral density (BMD) response varies with age remains unknown. Purpose: To examine BMD changes
Dupont, Jolan, Laurent, Michaël R, Viapiana, Ombretta, Gielen, Evelien, Dejaeger, Marian, Coppens, Désirée, De Vlam, Kurt, Adami, Giovanni, Amini, Nadjia, Rossini, Maurizio   +9 more
core   +2 more sources

Sclerostin and Cardiovascular Risk: Evaluating the Cardiovascular Safety of Romosozumab in Osteoporosis Treatment

Biomedicines
Background/Objectives: Osteoporosis and cardiovascular disease (CVD) share common risk factors and pathophysiological mechanisms, raising concerns about the cardiovascular implications of sclerostin inhibition.
Shi-Hsun Chiu, Wen-Tien Wu, Ting-Kuo Yao, Cheng-Huan Peng, Kuang-Ting Yeh   +4 more
doaj   +2 more sources

Impact of romosozumab on serum calcium concentration and factors predicting the fluctuations in calcium concentration upon romosozumab administration: A multicenter retrospective study

Bone Reports, 2022
Objectives: As romosozumab has both bone anabolic and antiresorptive effects, it is not clear which patient groups are more likely to have decreased calcium concentrations when treated with romosozumab. The aim of this study was to investigate the impact
Hiroyuki Inose, Tsuyoshi Kato, Shoji Tomizawa, Akane Ariga, Takayuki Motoyoshi, Kazuyuki Fukushima, Kunihiko Takahashi, Toshitaka Yoshii, Atsushi Okawa   +8 more
doaj   +1 more source

The Effects of Switch Therapy in Osteoporosis Treatment after Romosozumab after Comparing with Prior Treatment

Journal of Osteoporosis
Rationale. Although romosozumab is one of the most effective treatments for osteoporosis by increasing bone mineral density in the lumbar spine and femur and recommended for denosumab as switch therapy, these effects regarding its prior treatment have ...
Akira Horikawa, Yuji Kasukawa, Michio Hongo, Akihisa Sano, Naohisa Miyakoshi   +4 more
doaj   +2 more sources